Once‐a‐Day Highly Active Antiretroviral Therapy: A Systematic Review
Open Access
- 1 May 2003
- journal article
- review article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (9) , 1186-1190
- https://doi.org/10.1086/374602
Abstract
We analyzed the available evidence about the efficacy and tolerability of once-a-day highly active antiretroviral therapy (HAART), searching databaseKeywords
This publication has 7 references indexed in Scilit:
- Once‐Daily Quadruple‐Drug Therapy with Adefovir Dipivoxil, Lamivudine, Didanosine, and Efavirenz in Treatment‐Naive Human Immunodeficiency Virus Type 1–Infected PatientsThe Journal of Infectious Diseases, 2002
- Virological and Immunological Responses to a Once-a-Day Antiretroviral Regimen with Didanosine, Lamivudine and EfavirenzAntiviral Therapy, 2002
- A Pilot Trial of Indinavir, Ritonavir, Didanosine, and Lamivudine in a Once-Daily Four-Drug Regimen for HIV InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- Once‐Daily Combination Therapy with Emtricitabine, Didanosine, and Efavirenz in Human Immunodeficiency Virus–Infected PatientsThe Journal of Infectious Diseases, 2000
- Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV InfectionAnnals of Internal Medicine, 2000
- A simple, once-daily dosing regimen for treating HIV-1 infection in intravenous drug users.HIV Medicine, 2000
- Preliminary Experience of Adverse Drug Reactions, Tolerability, and Efficacy of a Once-Daily Regimen of Antiretroviral Combination TherapyJAIDS Journal of Acquired Immune Deficiency Syndromes, 2000